PL3354751T3 - Przeciwciała dla arypiprazolu i ich zastosowanie - Google Patents

Przeciwciała dla arypiprazolu i ich zastosowanie

Info

Publication number
PL3354751T3
PL3354751T3 PL18161262T PL18161262T PL3354751T3 PL 3354751 T3 PL3354751 T3 PL 3354751T3 PL 18161262 T PL18161262 T PL 18161262T PL 18161262 T PL18161262 T PL 18161262T PL 3354751 T3 PL3354751 T3 PL 3354751T3
Authority
PL
Poland
Prior art keywords
aripiprazole
antibodies
Prior art date
Application number
PL18161262T
Other languages
English (en)
Inventor
Eric Hryhorenko
Banumathi Sankaran
Thomas R. DECORY
Theresa TUBBS
Linda COLT
Bart M. REMMERIE
Rhys Salter
Ronghui Lin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3354751T3 publication Critical patent/PL3354751T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL18161262T 2012-08-21 2013-08-20 Przeciwciała dla arypiprazolu i ich zastosowanie PL3354751T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261691522P 2012-08-21 2012-08-21
EP13830375.5A EP2888373B1 (en) 2012-08-21 2013-08-20 Antibodies to aripiprazole and use thereof
EP18161262.3A EP3354751B1 (en) 2012-08-21 2013-08-20 Antibodies to aripiprazole and use thereof
PCT/US2013/055787 WO2014031640A2 (en) 2012-08-21 2013-08-20 Antibodies to aripiprazole and use thereof

Publications (1)

Publication Number Publication Date
PL3354751T3 true PL3354751T3 (pl) 2020-03-31

Family

ID=50148307

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18161262T PL3354751T3 (pl) 2012-08-21 2013-08-20 Przeciwciała dla arypiprazolu i ich zastosowanie
PL13830375T PL2888373T3 (pl) 2012-08-21 2013-08-20 Przeciwciała dla arypiprazolu i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13830375T PL2888373T3 (pl) 2012-08-21 2013-08-20 Przeciwciała dla arypiprazolu i ich zastosowanie

Country Status (10)

Country Link
US (3) US9494607B2 (pl)
EP (3) EP3663316A1 (pl)
JP (2) JP6270845B2 (pl)
CN (2) CN107325183B (pl)
AU (3) AU2013305879B2 (pl)
CA (1) CA2882562C (pl)
ES (2) ES2666000T3 (pl)
PL (2) PL3354751T3 (pl)
PT (2) PT3354751T (pl)
WO (1) WO2014031640A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2887952B1 (en) 2012-08-21 2019-05-15 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
EP3321254B1 (en) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
EP3390455A1 (en) * 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
US10483164B2 (en) * 2017-11-14 2019-11-19 Taiwan Semiconductor Manufacturing Company Ltd. Semiconductor structure and method for manufacturing the same
CN112262153B (zh) * 2018-06-06 2024-07-09 国立研究开发法人产业技术综合研究所 高效的肝炎病毒的抗体诱导方法、抗体以及检测系统
WO2021236724A2 (en) * 2020-05-20 2021-11-25 Remd Biotherapeutics, Inc. Human endothelin receptor a (etar) antagonist antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
GB2204398B (en) 1987-04-27 1991-08-28 Unilever Plc Analytical test device for use in assays
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
ATE198891T1 (de) 1992-05-29 2001-02-15 Lilly Co Eli Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
JPH07247271A (ja) 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
DE69535855D1 (de) 1994-06-10 2008-11-20 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
ATE380818T1 (de) 2002-03-28 2007-12-15 Lilly Co Eli Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
CA2494109A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
ATE361289T1 (de) 2002-08-05 2007-05-15 Lilly Co Eli Piperazinsubstituierte arylbenzodiazepine
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
NZ575575A (en) 2003-08-18 2010-04-30 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
EP1664007B1 (en) 2003-09-23 2009-12-23 Fermion Oy Preparation of quetiapine
KR20140015122A (ko) 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
ATE449337T1 (de) 2003-12-12 2009-12-15 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7658991B2 (en) * 2004-10-21 2010-02-09 University Of Georgia Research Foundation, Inc. Structures having aligned nanorods and methods of making
US20070255094A1 (en) * 2005-03-14 2007-11-01 Oepen Randolf V Crack/fatigue resistant endoprosthesis
US7837726B2 (en) * 2005-03-14 2010-11-23 Abbott Laboratories Visible endoprosthesis
US20060235005A1 (en) * 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
JP2008538767A (ja) * 2005-04-22 2008-11-06 ジェネンテック・インコーポレーテッド Ｃｄ２０抗体による認知症又はアルツハイマー病の治療方法
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CA2672972C (en) * 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
AU2008303540B2 (en) 2007-09-27 2012-04-26 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
BRPI0916366B1 (pt) 2008-07-21 2021-08-10 Probiodrug Ag Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CA2736335C (en) 2008-10-14 2017-05-09 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
CA2742074A1 (en) 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
SI2459220T1 (sl) 2009-07-31 2020-12-31 Ascendis Pharma A/S Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
WO2011042450A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
EP2790734B1 (en) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
BR112015003393A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
JP6171014B2 (ja) 2012-08-21 2017-07-26 ヤンセン ファーマシューティカ エヌ．ベー． オランザピン（Ｏｌａｎｚｉｐｉｎｅ）のハプテン
EP3321254B1 (en) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
CN104736536B (zh) 2012-08-21 2018-09-25 詹森药业有限公司 用于免疫测定的喹硫平半抗原
EP2887952B1 (en) 2012-08-21 2019-05-15 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
TR201911272T4 (tr) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Paliperidon haptenleri.
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
EP2888373A4 (en) 2016-05-11
US10175257B2 (en) 2019-01-08
US20140057300A1 (en) 2014-02-27
AU2018200278A1 (en) 2018-02-01
JP2015531768A (ja) 2015-11-05
HK1260330A1 (en) 2019-12-20
US20170030936A1 (en) 2017-02-02
CA2882562C (en) 2019-08-27
JP6567033B2 (ja) 2019-08-28
EP2888373B1 (en) 2018-03-14
JP2018118961A (ja) 2018-08-02
ES2762105T3 (es) 2020-05-22
WO2014031640A3 (en) 2014-05-01
CN107325183A (zh) 2017-11-07
CA2882562A1 (en) 2014-02-27
CN107325183B (zh) 2021-06-04
EP3663316A1 (en) 2020-06-10
AU2019284031A1 (en) 2020-01-23
US20190128904A1 (en) 2019-05-02
PL2888373T3 (pl) 2018-08-31
US10816561B2 (en) 2020-10-27
HK1211989A1 (en) 2016-06-03
EP3354751A1 (en) 2018-08-01
PT2888373T (pt) 2018-06-12
AU2013305879B2 (en) 2017-10-12
AU2013305879A1 (en) 2015-03-05
EP2888373A2 (en) 2015-07-01
CN104755631A (zh) 2015-07-01
WO2014031640A2 (en) 2014-02-27
PT3354751T (pt) 2019-12-17
AU2018200278B2 (en) 2019-09-26
AU2018200278B9 (en) 2019-10-31
AU2019284031B2 (en) 2022-03-31
CN104755631B (zh) 2017-09-05
ES2666000T3 (es) 2018-04-30
JP6270845B2 (ja) 2018-01-31
US9494607B2 (en) 2016-11-15
EP3354751B1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
PL2888373T3 (pl) Przeciwciała dla arypiprazolu i ich zastosowanie
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
SG11201407099WA (en) Anti-pcsk9 antibodies and use thereof
IL238559A0 (en) Antibodies against ceacam5 and their use
PL3462173T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof
IL254416A0 (en) Anti-asic1 antibodies and their uses
PL3333195T3 (pl) Przeciwciała względem kwetiapiny i ich zastosowania
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PT2888590T (pt) Anticorpos para olanzapina e utilização destes
GB201208372D0 (en) Antibodies and uses thereof